Chimeric (ASX:CHM) share price edges lower despite positive update

The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in afternoon trade despite a positive update. Here's what the company said.

| More on:
asx share price fall represented by lady in striped tshirt making sad face against orange background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The Chimeric Therapeutics Ltd (ASX: CHM) share price is sliding in mid-afternoon trade. This comes despite the company announcing the successful completion of its CLTX CAR T phase 1 trial.

Established in 2020, Chimeric is developing a breakthrough cancer cell therapy drug for solid tumours. The company uses chlorotoxin, which comes from scorpion venom, to bind and direct T cells to target glioblastoma (GBM). Initial scientific research conducted at the City of Hope Cancer Centre in Los Angeles found promising anti-tumour activity from CAR T therapy.

At the time of writing, the biotechnology company's shares are going for 29 cents apiece, down 1.6%.

What did Chimeric announce?

Investors appear unfazed by the company's latest update, sending Chimeric shares lower.

According to its release, Chimeric advised it has passed the first checkpoint in the City of Hope's phase 1 CLTX CAR T cell clinical trial. All patients in the first group that received the Chlorotoxin CAR T dose have exceeded the 28-day follow-up period without experiencing dose-limiting toxicities.

The dose-escalation study is seeking to assess Chlorotoxin CAR T's safety and maximum tolerance in participants suffering from recurrent or progressive GBM.

While the first cohort received the minimum dosage limit, Chimeric will now move onto the second dosing level. Patients in this group will be administered via two methods – intratumoral (ICT) and intracranial intraventricular (ICV) at a total dose of 88 x 106 CAR T cells.

Chimeric hopes to recruit between 18 to 36 people with MMP2+ recurrent or progressive GBM across 4 different dose levels. Once the appropriate dosing amount is established, the company will then move to phase 2 trials.

Chimeric chief operating officer, Jennifer Chow commented on the achievement:

We are very pleased to have reached this significant milestone with our CLTX CAR T cell therapy as it enables us to advance the development of this important therapy for patients with progressive or recurrent Glioblastoma.

We look forward to further progressing the development of CLTX CAR T and to providing updates as we seek to bring the promise of cell therapy to life for more patients with cancer.

About the Chimeric share price

Since coming online to the ASX at the start of this year, the Chimeric share price has remained relatively flat. The company's shares reached an all-time high of 44 cents in late January, before treading lower.

Based on the current share price, Chimeric has a market capitalisation of roughly $57 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Unsure man analysing data on laptop.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the week this Monday.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Guess which popular ASX 200 stock Bell Potter just downgraded

Let's see what the broker is saying on this blue chip.

Read more »

Crude oil barrels rocketing.
ETFs

Why did the BetaShares Crude Oil ETF just spike 4%?

This ETF is attracting buyers in today's seller's market.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why BWP, Metcash, Resolute Mining, and SHAPE shares are pushing higher today

These shares are starting the week on a positive note. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Adairs, ANZ, Aurelia Metals, and Pilbara Minerals shares are falling today

These shares are having a tough start to the week in the red. But why?

Read more »

Miner standing in a mine site with his arms crossed.
Broker Notes

Up 41% in 2025, does Macquarie think Lynas Rare Earths shares have peaked?

The company is up nearly 400% in 5 years.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Share Market News

How far could equity markets fall following the US' attack on Iran?

If oil prices rise, it could be bad news for investors.

Read more »